The Brugada Syndrome Market was valued at USD 1.35 billion in 2024 and is projected to grow from USD 1.42 billion in 2025 to USD 2.2 billion by 2033, recording a CAGR of 5.58% during the forecast period. Growth is being driven by the increasing prevalence of Brugada syndrome worldwide, coupled with better awareness and improved diagnostic techniques that help in preventing sudden cardiac death.
Market Growth Drivers
One of the primary factors accelerating market growth is the rising prevalence of Brugada syndrome, which affects an estimated 3 to 5 per 10,000 individuals globally. Prevalence is significantly higher in Southeast Asia compared to other regions. Additionally, advancements in genetic testing, pharmacological challenges, and electrophysiological studies have enhanced diagnosis, reducing misdiagnosis cases. Awareness initiatives such as the Brugada Foundation and Brugada Dravet Syndrome Awareness Day are also improving recognition and early intervention.
Restraining Factors
A major challenge is the lack of safe and efficient treatment options. While implantable cardioverter-defibrillators (ICDs) remain the standard treatment, they come with drawbacks such as infection risks, high costs, and limited accessibility in low- and middle-income regions. This creates demand for safer, more cost-effective alternatives.
Opportunities Ahead
The market is witnessing a rise in innovative treatment solutions, including subcutaneous ICDs (S-ICDs) and emerging gene therapy approaches. Notably, researchers at the Cleveland Clinic developed a gene therapy in 2022 that showed promising results in treating Brugada syndrome in mice. Experimental drugs like AR-787, designed to target sodium channels, are also opening new avenues for treatment.
Regional Insights
- North America: Strong presence of players such as Boston Scientific, Medtronic, and Abbott, along with favorable reimbursement policies, is fueling market expansion.
- Asia-Pacific: Expected to record the fastest growth due to high prevalence rates, particularly in Southeast Asia where the condition is often linked to Sudden Unexplained Nocturnal Death Syndrome (SUNDS). Thailand reports the highest global prevalence.
- Europe and Rest of World: Growth driven by improving healthcare infrastructure, awareness, and genetic predisposition factors in certain regions.
Diagnosis and Treatment Breakdown
- Diagnosis: Electrocardiogram (ECG) remains the largest segment, supported by its accessibility and non-invasive nature.
- Treatment: Implantable cardioverter-defibrillators (ICDs) dominate, with ongoing research into drug therapy and next-gen devices.
- End-Users: Hospitals and clinics lead the segment due to their comprehensive care facilities and reimbursement support.
Key Players in the Brugada Syndrome Market
- Abbott
- Boehringer Ingelheim International
- Ionis Pharmaceuticals
- Catalyst Pharmaceuticals Inc
- Natera Inc
- Novo Nordisk A/S
- Pfizer Inc
- Leadiant Biosciences Inc
- PTC Therapeutics
- Roche
- Salarius Pharmaceuticals Inc
- Novartis AG
- Takeda Pharmaceuticals
Recent Developments
- May 2023: Samsung Electronics received FDA clearance for its Irregular Heart Rhythm Notification (IHRN) feature in the Samsung Health Monitor app.
- October 2023: Vektor Medical’s non-invasive arrhythmia analysis tool vMap® was granted a new Category III CPT code by the American Medical Association (AMA).
About Us:
Straits Research is a leading global market intelligence and consulting firm, dedicated to delivering actionable insights and in-depth analysis across a wide range of industries. Our mission is to empower organizations, investors, and decision-makers with reliable data, strategic guidance, and forward-looking perspectives to help them thrive in a rapidly evolving business landscape.
Contact Us:
Email: [email protected]
Tel: +1 646 905 0080 (U.S.), +44 203 695 0070 (U.K.)
Website: https://straitsresearch.com/
